LEP and primary biliary cholangitis: However, the food and drug administration (FDA) approval of TUDCA for the treatment of primary biliary cirrhosis (Invernizzi et al., 1999) and its inhibitory potential against influenza A viral replication by inducing ER stress (Hassan et al., 2012) are to be controversial for its application in leptin/leptin signaling impaired pathologies.